

Risk Analysis of Specific Environmental Heavy Metals as a Trigger of CD4 & CD8 among Cases of Multiple Sclerosis: Case-control study

Elberry R. A.^{*1} MSc, Alazab R.² PhD, Abdel Hady A.¹, Sobh k.²PhD, Abdellatif S.²PhD and ELSayed A.²MD

***Corresponding Author:**

Elberry, Reda Ataarabeh

elberryreda@gmail.com

Received for publication April 13,

2020; Accepted July 3, 2020;

Published online July 3, 2020.

Copyright 2020 The Authors published by Al-Azhar University, Faculty of Medicine, Cairo, Egypt. All rights reserved. This an open-access article distributed under the legal terms, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

doi:

10.21608/aimj.2020.27847.1198

¹Department of Community Medicine and Occupational Medicine, Faculty of Medicine, Al-Azhar University, Assuit, Egypt

²Department of Community Medicine and Occupational Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

ABSTRACT

Background: Environmental pollutants might be among the etiological factors for multiple sclerosis. The high rise of CD8 and CD4 is the commonly accepted pathway for the chronic inflammation of myelin sheath proteins developing the different clinical types of MS.

Objectives: To measure the level of blood lead, cadmium, mercury, CD4 and CD8 among the different clinical types of MS cases compared to controls, to find out if there is a correlation between the level of the measured heavy metals and the degree of disability among the studied cases of multiple sclerosis.

Methodology: Case-Control study was conducted at El-Hussein University Hospital, Cairo, Egypt during the period (April 2017-February 2020). The calculated sample size was 50 for cases and controls. Subjects were selected by a simple random technique.

Results: Mean blood lead of cases was higher than observed among controls ($62.1 \pm 3.2 \mu\text{g/L}$ versus $19.3 \pm 1.5 \mu\text{g/L}$) with statistically significant difference $p=0.000001$. Regarding blood mercury: mean among cases was higher than controls ($25.1 \pm 0.88 \mu\text{g/L}$ versus $2.3 \pm 0.2 \mu\text{g/L}$) with a statistically significant difference between two groups by Levine's t-test ($t=5.5$, $p=0.000001$). There was a positive correlation between lead and Mercury with CD4 and CD8 among cases of Relapsing-Remitting MS and cases of Primary Progressive MS.

Conclusion: Lead and Mercury might be a risk factor for trigger CD4 and CD8 among the studied cases of MS.

Keywords: multiple sclerosis; lead, mercury; CD4; CD8

Disclosure: The author has no financial interest to declare in relation to the content of this article. The Article Processing Charge was paid for by the author.

Authorship: All authors have a substantial contribution to the article.

INTRODUCTION

Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory neurological disease of the central nervous system that attacks the myelinated axons and destroying them in variable degrees¹. The clinical manifestations of multiple sclerosis are very variable and include motor, sensory, visual and cognitive symptoms, none of them being disease specific². Focal inflammatory plaques and axonal loss are considered as a main pathological feature of MS, while the question about the etiology of MS is still unresolved³.

Environmental agents are believed to trigger a T-cell-mediated chronic inflammatory response to myelin proteins in individuals with a genetic predisposition, creating the characteristic lesions that cause disease⁴. Numerous immune populations are important in MS development. Among these, CD8⁺ T cells and CD4⁺ T cells have appeared as potential major effectors within the CNS⁵.

Overexposure to lead and mercury ions is known to be neurotoxic, particularly to motor neurons. Low-to-moderate levels of lead exposure can cause functional alterations in T-lymphocytes and macrophages that lead to increased hypersensitivity and alter cytokine production, which increases the risk of inflammation-associated tissue damage⁶. Also, it has been observed that lead and cadmium toxicity contribute to a vast variety of important disease conditions such as neurological disorders, cancer, cognitive impairments, hypertension, heart disease, and diabetes⁷. The present study tried to study the possible cause of multiple sclerosis, via measuring the level of lead, cadmium, and mercury among the studied cases and controls, to find out if there a correlation between the level of the studied heavy metals and the degree of disability among the studied cases of multiple sclerosis and to determine the extent of association between the elevated CD4 and CD8 among the studied cases with an elevated level of heavy metals.

Objectives

To measure the level of lead, cadmium, and mercury among the studied cases and controls, to find out if there is a correlation between the level of the measured heavy metals and the degree of disability among the studied cases of multiple sclerosis and to determine the level of CD4 and CD8 among the studied cases with an elevated level of heavy metals.

SUBJECT AND METHODS

Type of the study:

A case-control study was conducted at El-Hussein University Hospital during the period (April 2017- Feb 2020).

Sample size estimation:

The sample size was estimated by the epi info program using the following data: Confidence level: 95%, Power of the study:80%, Ratio of controls to cases=1:1, Percentage of controls exposed=1.4 % and Percentage of cases with exposure=18%⁸. The estimated minimum sample size required is 50 cases and 50 controls.

Sampling:

Cases and controls were selected by a simple random technique by using random number tables as following: All cases of MS and relatives to patients attended Al Hussein MS clinic on Sunday and Wednesday were recorded, The duration of selection was one year, Total number of recorded cases and controls on Sunday during one year was 105 cases and 106 controls, the total number of recorded cases and controls on Wednesday during one year was 106 cases and 106 controls, by table 2 of Random numbers tables, 25 cases, and 25 controls were selected from all recorded cases and controls, by table 5 of Random numbers tables, 25 cases, and 25 controls were selected from all recorded cases and controls.

Inclusion criteria for cases: Cases with a diagnosis of definite, probable, or possible MS. Exclusion criteria for

cases and controls: Cases with advanced renal, cardiac, respiratory, or liver diseases or other neurological diseases. **Methods:** All cases and controls were subjected to interview medical sheet. Clinical diagnosis and disability degree of MS typewere conducted and recorded by the neurologist at MS clinicusing an expanded disability status scale (EDSS)⁹. Laboratory investigations: blood lead, cadmium, mercury, CD4, and CD8 were conducted for cases and controls.

Determination of risk level

This thesis used a risk rating exposure levelmethod to analyze the risk.

Data analysis

Data collected and presented in the tables and charts using the Epi info program. P <0.05 was accepted as a level of significance, Chi-square, mean± SD, odds ratio, t-test, F test, and correlation Coefficient were the statistical tests used in the present study.

RESULTS

As regards gender there is a higher percentage of multiple sclerosis among females compared to males (64% and 36% respectively) with ratio 2:1 and the difference was statistically significant. (X² =1.126, P=0.045). It was observed that multiple sclerosis cases were more prevalent among age group (20-<25 years). As regards residency was revealed that multiple sclerosis cases were more prevalent among Urban area than the rural area (14% and 16% respectively) and the difference was statistically significant. (X² =0.396, P=0.03) (Figure 1)




Fig. 1: shows that relapsing-remitting MS was the highest prevalent clinical type of MS among the studied cases. It represents 76%.

	Relapsin g- remitting MS (N: =38) N. %	Contr ol (N: =38) N. %	Chi 2	P valu e	Odd s rati o
Lead	38	3	64.8	0.0*	62.3
Cadmium	100.0	7.9	NA	NA	NA
Mercury	0 0.0 29 76.3	0 0.0 2 5.3	39.7	0.0*	10.6

Table 1: Distribution of elevated Blood lead, Cadmium, and Mercury among cases of Relapsing-remitting multiple sclerosis.

*: significant

NA: Not Applicable

Table 1: Shows that all cases were suffering from elevated blood lead while only 7.9 % of controls were revealed elevated blood lead with a statistically significant difference (p=0.00). Regarding cadmium, all cases and controls were within normal levels. As regards, mercury 76.3% of cases revealed elevated blood mercury while 5.3% of controls revealed elevated blood mercury with a statistically significant difference (p=0.00).

	Primary-progressive MS (N: =7)		Control (N.=7)	Chi 2	P value	Odds ratio
	N.	%	N. %			
Lead	7		3	64.8	0.0*	62.3
Cadmium	100		42.8	NA	NA	NA
Mercury	0		0	7.7	0.005*	1.4
	0.0		0.0			
	5		0			
	71.4		0.0			

Table 2: Distribution of elevated Blood lead, Cadmium and Mercury among cases of Primary-progressive multiple sclerosis.

*: significant

NA: Not Applicable

Table 2: Shows that all cases were suffering from elevated blood lead while only **42.8** % of controls were revealed elevated blood lead with a statistically significant difference (p=0.00). Concerning cadmium, all cases and controls were within normal levels. As regards mercury **71.4** % of cases revealed elevated blood mercury while none of the controls revealed elevated blood mercury with a statistically significant difference (p=0.005).

Lead, Mercury, Cadmium & immune cells CD4 and CD 8	Studied groups			
	Cases (N: =50)	Controls (N: =50)	t Test	P-value *: significant
Lead (normal = 0.0-25.0 µg/dl)				
Mean ± SD	62.1 ± 3.2 µg/L	19.3±1.5µg/L	7.700	0.000001*
Range	32.9-101.3 µg/L	14.8-43.6 µg/L		
Mercury (normal=0.0-10.0 µg/dl)				
Mean ± SD	25.1 ± 0.88 µg/L	2.3 ± 0.2 µg/L	5.5	0.000001*
Range	0.22-29.98 µg/L	0.3-12.8 µg/L		
Cadmium (normal=0.0-5.0µg/dl)				
Mean ± SD	1.99 ± 0.18 µg/L	1.3± 0.2µg/L	18.1	0.000001*
Range	1.81-2.17 µg/L	0.16-2.1 µg/L		
CD4 (500 – 1500 cells / µl).				
Mean ± SD	2513.87±21.09 cells/µl	1233.3 ±9.1 cells/µl	1394.2	0.00000001*
CD 8 (400 – 1200 cells/ µl).				
Mean ± SD	2269.1±80.8 cells/µl	789.7±16.02 cells/µl	126.9	0.000001*

Table 3: Mean ± S.D. of blood Lead, Mercury, Cadmium, and immune cells CD4 and CD 8 among the studied groups.

Table 3: shows that the mean blood lead of cases was higher than observed among controls (62.1±3.2 µg/L versus 19.3±1.5µg/L) with statistically significant difference p=0.000001). Regarding blood mercury: mean among cases was higher than controls (25.1 ± 0.88 µg/L versus 2.3 ± 0.2 µg/L) with a statistical significant difference between two groups by Levine's t-test (t=5.5, p=0.000001). As regards the blood cadmium: mean among cases was higher than control (1.99 ± 0.18 µg/L versus 1.3± 0.2µg/L) with statistically significant difference (p=0.000001). As regards the blood CD4: mean among cases was higher than control (2513.87±21.09 cells/µl versus 1233.3 ±9.1 cells/µl) with a statistical significant difference between (p=0.00000001*) and regarding the blood, CD8 mean among cases was higher than control (2269.1±80.8 cells/µl versus 789.7±16.02 cells/µl) with statistically significant difference (p=0.000001).

Clinical types of MS	Lead and Mercury	Correlation Coefficient (r)	
		CD4	CD8
Relapsing-remitting RRMS (N: =38)	Lead (Range=32.9-79 µg/dL)	r = 0.850 p=0.000*	r = 0.576 p=0.000*
	Mercury (Range=0.22-19 µg/dL)	r = 0.692 p=0.000*	r = 0.330 p=0.043*
Primary-progressive PPMS (N: =7)	Lead (Range=71-99 µg/dL)	r = 0.736 p=0.059	r = 0.773 p=0.042*
	Mercury (Range=10.25-15.6 µg/dL)	r = 0.878 p=0.009*	r = 0.955 p=0.001*

Table 4: Correlation coefficient between levels of lead and mercury and the levels of CD4 and CD8 among the relapsing-remitting multiple sclerosis and Primary-progressive multiple sclerosis.




Fig. 2: Shows that EDSS 2 (Expanded Disability Status Scale) was the more prevalent disability type among studied cases followed with EDSS 1, EDSS 4 (46%, 28%, and 22% respectively).

Different groups of Expanded Disability Status Scale (EDSS)	Lead, Cadmium and Mercury	CD4	CD 8

EDSS 1 (N: =14)	Lead	r =0.981 p=0.000*	r =0.982 p=0.000*
	Mercury	r =0.980 p=0.000*	r =0.988 p=0.000*
EDSS 2 (N: =23)	Lead	r = 0.278 p=0.199	r =-0.457 p=0.028*
	Mercury	r =0.429 p=0.041*	r =-0.264 p=0.224
EDSS 4 (N: =11)	Lead	r =0.716 p=0.020*	r = 0.844 p=0.002*
	Mercury	r = 0.840 p=0.002*	r =0.977 p=0.000*

Table 5: Correlation Coefficient between levels of lead, cadmium and mercury and the levels of CD4 and CD8 among the different scales of Expanded Disability Status

Clinical types of multiple sclerosis	Heavy metals	Mean ± SD	Exposure severity	Risk Rating Level
Relapsing-remitting RRMS N: = 38	Lead (Normal=0-25 µg/dL)	57.1 ± 16.76	At or greater than normal	High
	Mercury (Normal= 0-10 µg/dL)	17.78 ± 5.60	Between 50-100% of normal	Moderate
	Cadmium (Normal= 0-5 µg/dL)	2.04 ± 0.29	Less than 50% of normal	Low
Secondary-progressive SPMS N: = 3	Lead (Normal=0-25 µg/dL)	66.66 ± 5.77	At or greater than normal	High
	Mercury (Normal= 0-10 µg/dL)	19.36 ± 0.56	Between 50-100% of normal	Moderate
	Cadmium (Normal= 0-5 µg/dL)	1.97 ± 0.17	Less than 50% of normal	Low
Primary-progressive PPMS N: = 7	Lead (Normal=0-25 µg/dL)	81.28 ± 9.56	At or greater than normal	High
	Mercury (Normal= 0-10 µg/dL)	12.73 ± 1.83	Between 50-100% of normal	Moderate
	Cadmium (Normal= 0-5 µg/dL)	1.93 ± 0.022	Less than 50% of normal	Low
Progressive-relapsing PRMS N: = 2	Lead (Normal=0-25 µg/dL)	100.65 ± 0.92	At or greater than normal	High
	Mercury (Normal= 0-10 µg/dL)	18.39 ± 2.25	Between 50-100% of normal	Moderate
	Cadmium (Normal= 0-5 µg/dL)	2.065 ± 0.148	Less than 50% of normal	Low

Table 6: Estimating the risk Rating Exposure Level of lead, cadmium, and mercury among the clinical types of multiple sclerosis.

Table 6: shows that the risk rating level of exposure to lead, mercury and cadmium was high (greater than normal 100% of normal), moderate (between 50-100% of normal) and low (less than 50% of normal) respectively among the studied clinical types of multiple sclerosis¹⁰.

DISCUSSION

As regards the distribution of elevated Blood lead, Cadmium and Mercury among relapsing-remitting multiple sclerosis **Table (1)**; the present study found that all cases revealed elevated blood lead representing 100% while only 3 controls revealed elevated blood lead representing 7.9% with a statistically significant difference between two groups ($p=0.00$) and (odds ratio 62.3). This is higher than found by Mohammad Dehghanifiroozabadi¹¹ who stated that the risk of MS increased 1.17 times per one $\mu\text{g}/\text{dL}$ increment of blood lead level

As regards the distribution of elevated Blood lead, Cadmium, and Mercury among cases of Primary-progressive multiple sclerosis **Table (2)**; the present study revealed that all cases were suffering from elevated blood lead while only 42.8% of controls were revealed elevated blood lead with statistically significant difference ($p=0.00$). In regards to cadmium, all cases and controls were within normal levels. As regards mercury 71.4% of cases revealed elevated blood mercury while none of the controls revealed elevated blood mercury with a statistically significant difference ($p=0.005$). Zahra Razavi¹² had found that 35.29% of multiple sclerosis cases with blood lead $<20 \mu\text{g}/\text{dL}$ and 12.50% of multiple sclerosis cases with blood lead $20 -100 \mu\text{g}/\text{dL}$. This might be said that lead is not a contributing factor to the pathogenesis of MS.

As regards the mean values of lead, mercury, cadmium and immunological cells CD4, CD8 among MS cases it was found a statistically significant difference between all cases of multiple sclerosis and controls **table(3)**; This inline with Zahra Razavi¹² who found that blood lead level $<20 \mu\text{g}/\text{L}$ in 47.06% of clinical type relapsing-remitting multiple sclerosis and 35.29% of clinical type secondary progressive multiple sclerosis and 17.65% of clinical type clinically isolated multiple sclerosis also $20-100 \mu\text{g}/\text{L}$ in 50.00% of clinical type relapsing-remitting multiple sclerosis and 12.50% of clinical type secondary progressive multiple sclerosis and 37.65% of clinical type clinically isolated multiple sclerosis and $100-100 \mu\text{g}/\text{L}$ in 83.00% of clinical type relapsing-remitting multiple sclerosis and 0.0% of clinical type secondary progressive multiple sclerosis and 16.76% of clinical type clinically isolated multiple sclerosis during his study the relationship between blood Lead Levels and clinical features among multiple sclerosis patients in Isfahan, Iran

As regards the distribution of multiple sclerosis cases according to Expanded Disability Status Scale (EDSS) Figure (6); the present study revealed that EDSS 2 (Expanded Disability Status Scale 2) was the more prevalent disability types among the studied cases followed with EDSS 1 and EDSS 4 (46%, 28%,

22% respectively). This is in line with Zahra Razavi¹² who had found that EDSS 2 (Expanded Disability Status Scale) was the more prevalent disability type among the studied cases followed by EDSS 1, EDSS 4 and EDSS 6 (52.00%, 25.08%, 18.75%, 4.17% respectively).

The present study assumes that cases of MS might be developed because of the pollutant effects of Lead and Mercury which trigger the elevation of CD8 and CD4 leading to the chronic inflammation of myelin sheath. This might be explained by studies in experimental allergic encephalomyelitis (EAE), histopathological studies of MS lesions, and immunologic markers in serum and cerebrospinal fluid of MS patients suggest that MS is an immune-mediated disease and environmental toxin might induce an immune response in genetically susceptible persons Prineas¹³, Also, Frohman¹⁴ stated that antigen-presenting cells (APCs) provide relevant antigens to CD4+ T helper cells in the periphery, which lead to their activation and the subsequent generation of autoreactive pro-inflammatory T helper (Th) 1 and 17.

The presenting study claims that lead and mercury might lead to induction of increasing the level of CD4 and CD8, this is supported with the findings of the present study which found a statistically significant difference between cases and controls with high odds ratio as regards lead and mercury among the different clinical types of MS (Table 1 and 2) and highly statistically significant difference between cases and controls as regards CD4 and CD8 (Table 3). Also, table 4 shows a positive correlation between the level of lead, mercury, and CD4, CD8 with a statistical significance difference. It was noted in the present study that these observations were found among cases of relapsing-remitting MS and primary progressive MS. Also, the same findings were observed among EDSS 1, EDSS 2, and EDSS 4. This inline with Zahra Razavi¹² who found that Lead exposure is one of the environmental factors considered to play a role in the etiopathogenesis of MS.

The present study found that elevation of blood lead and mercury trigger the elevation of CD4 and CD8 (**Table 4**). This inline with Chibowska¹⁵ who concluded that Exposure to lead may result in microgliosis and astrogliosis by triggering a signaling cascade and the production of proinflammatory cytokines. On the other hand, Zahra Razavi¹² reported that Lead produces MS through its ability to be attached to myelin proteins and act as a hapten. He added that; some researchers consider that lead is responsible for the formation of antibodies against myelin proteins and thereby can play a role in the pathogenesis of neurological diseases, particularly in MS.

As regards mercury, it was demonstrated that; acute Methyl mercury poisoning leads to a stimulation of the immune system, especially of cytotoxic CD8+ T cells, whereas CD4+ T cell number and activation remain unaltered. Of note, certain functionally and phenotypically distinct subpopulations of thymic-derived CD4+ T regulatory cells can control and limit potentially harmful immune responses Kleffner¹⁶.

However, Höftberger¹⁷ reported that; Studies strongly suggest that infiltrating CD8 T lymphocytes in the CNS of patients with MS selectively enter this organ. Unfortunately, the antigen specificity of these infiltrating CD8 T lymphocytes remains still unknown. Under basal physiological conditions, CNS cells including neurons, oligodendrocytes, and astrocytes express low levels of MHC class I molecules, which are recognized by CD8 T lymphocytes. However, up-regulated MHC class I is observed on resident CNS cells in MS lesions even in the initial phases of the disease). This in accordance with Kebir¹⁸ who stated that; the presence of CD8 T lymphocytes in MS lesions positively correlates with the extent of axonal damage. Several studies reported enrichment of IL-17-producing CD8 T lymphocytes (i.e., Tc17) in MS lesions. Recent data support that both CD4 and CD8 T lymphocytes work in concert to cause the autoimmune attack observed in EAE. Additional investigations on the interplay between CD4 and CD8 T lymphocytes during different phases of MS and EAE could shed light on the complex and heterogeneous immune mechanisms involved in the disease pathobiology¹⁹. It has been suggested that CD8 T lymphocytes can kill myelin-specific CD4 T lymphocytes in a HLA-E restricted manner, Correale and Villa²⁰

The present study found that lead was high risk, mercury was a moderate risk and cadmium was low risk among cases of multiple sclerosis in estimating risk rating among cases of multiple sclerosis Table (6); This agrees with present study that found lead is high in all EDSS and is correlated with an increase of CD4 and CD8 in different groups of EDSS. These findings encourage the need for more environmental studies that measure the level of lead and mercury in air, water, and food products to make a match between biological monitoring and environmental monitoring.

CONCLUSION

Lead and Mercury might be a risk factor for trigger CD4 and CD8 among the studied cases of MS.

REFERENCES

1. Naderi N. The Perspectives of Mesenchymal Stem Cell Therapy in the Treatment of Multiple Sclerosis. *Iran J Pharm Res.* 2015 Winter;14(Suppl):1-2. PMID: 26185500; PMCID: PMC4499421.
2. Goldenberg MM. Multiple sclerosis review. *P T.* 2012 Mar;37(3):175-84. PMID: 22605909; PMCID: PMC3351877.
3. Koch MW, Metz LM, Agrawal SM, Yong VW. Environmental factors and their regulation of immunity in multiple sclerosis. *J Neurol Sci.* 2013 Jan 15;324(1-2):106. doi:10.1016/j.jns.2012.10.021. Epub 2012 Nov 13. PMID: 23154080; PMCID: PMC7127277.
4. Napier MD, Poole C, Satten GA, et al. Heavy metals, organic solvents, and multiple sclerosis: An exploratory look at gene-environment interactions. *Arch Environ Occup Health.* 2016;71(1):26-34. doi: 10.1080/19338244.2014.937381. Epub 2014 Aug 19. PMID: 25137520; PMCID: PMC4334728.
5. Sinha S, Itani FR, Karandikar NJ. Immune regulation of multiple sclerosis by CD8+ T cells. *Immunol Res.* 2014 Aug;59(1-3):254-65. doi: 10.1007/s12026-014-8529-9. PMID: 24845461; PMCID: PMC4125494.
6. Attar, Kharkhaneh, Etemadifar, et al. Serum Mercury Level and Multiple Sclerosis. *Biol Trace Elem Res* 146, 150–153(2012). <https://doi.org/10.1007/s12011-011-9239-y>
7. Solomon, A.J., Whitham, R.H. Multiple Sclerosis and Vitamin D: A Review and Recommendations. *Curr Neurol Neurosci Rep* 10, 389–96 (2010). <https://doi.org/10.1007/s11910-010-0131-5>
8. El-Tallawy HN, Farghaly WM, Badry R, et al. Prevalence of multiple sclerosis in Al Quseir city, Red Sea Governorate, *Egypt. Neuropsychiatric Dis Treat.* 2016 Jan 13;12:155-8. doi: 10.2147/NDT.S87348. PMID: 26834477; PMCID: PMC4716737.
9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale(EDSS). *Neurology*, 1983;33(11):1444; doi: 10.1212/WNL.33.11.1444
10. SIMRAC. Handbook of occupational health practice in the South African Mining Industry (2001). ISBN: 978-0-9559983-2-4.

11. Fulgenzi, Zanella, S.G., Mariani, M.M, et al. A case of multiple sclerosis improvement following removal of heavy metal intoxication. *Biometals* 25, 569–76 (2012). <https://doi.org/10.1007/s10534-012-9537-7>.
12. Zahra Razavi, Mojtaba Jokar, Alireza Allafchian, et al. The Relationship between Blood Lead Levels and Clinical Features among Multiple Sclerosis Patients in Isfahan, Iran, *Iranian Journal of health, Safety and environment*, 2015, Vol.3, No.1, pp.412-20.
13. Prineas, J.W. and Parratt, J.D.E. (2012), Oligodendrocytes and the early multiple sclerosis lesion. *Ann Neurol.*, 72: 18-31. doi:10.1002/ana.23634.
14. Teresa C. Frohman, Shin C. Beh, Eric J. Kildebeck, et al. Neurotherapeutic Strategies for Multiple Sclerosis, *Neurol clinc.* 2016 Aug;34(3):483-523. doi: 10.1016/j.ncl.2016.05.001.
15. Chibowska K, Baranowska-Bosiacka I, Falkowska A, Gutowska I et al. Effect of Lead (Pb) on Inflammatory Processes in the Brain. *Int J Mol Sci.* 2016 Dec 19;17(12):2140.doi:10.3390/ijms17122140 PMID: 27999370; PMCID: PMC5187940.
16. Kleffner I, Eichler S, Ruck T, Schüngel L, et al. An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function. *Front Neurol.* 2017 Sep 28;8:517. doi: 10.3389/fneur.2017.00517. PMID: 29033890; PMCID: PMC5625000.
17. Höftberger, Aboul-Enein, Brueck, et al. Expression of Major Histocompatibility Complex class I Molecules on the Different Cell Types in Multiple Sclerosis Lesions. *Brain Pathology*, 14: 43-50. doi:10.1111/j.1750-3639.2004.tb00496.x.
18. Ifergan, I., Kebir, H., Terouz, S., et al. Role of ninjurin-1 in the migration of myeloid cells to central nervous system inflammatory lesions. *Ann Neurol.*, 70: 751-63. doi:10.1002/ana.22519.
19. Legroux L, Arbour N. Multiple Sclerosis and T Lymphocytes: An Entangled Story. *J Neuroimmune Pharmacol.* 2015 Dec;10(4):528-46. doi: 10.1007/s11481-015-9614-0. Epub 2015 May 7. PMID: 25946987; PMCID: PMC5052065.
20. Correale, Villa. Isolation and characterization of CD8 regulatory T cells in multiple sclerosis. *Journal of neuroimmunology.* 195. 121-34. 10.1016/j.jneuroim.2007.12.004.